Tag Archives: pfizer

Pfizer lays out timeline for its COVID-19 vaccine and a new flu vaccine

Vial of Pfizer’s COVID-19 vaccine

Photo: Arne Müseler via Flickr

In a teleconference announcing the company’s first-quarter 2021 earnings earlier this month, Pfizer laid out its timeline for when different versions of its COVID-19 vaccine may become available for various populations. The company also said it is working on two approaches for an mRNA-based flu vaccine (similar technology as the COVID-19 vaccine), with plans to run clinical trials in the third quarter.

By the end of May, the New York City company expects to submit a biologics license application (BLA) asking the FDA to fully approve the vaccine rather than continue its use under an emergency use authorization (EUA). Continue reading

Pfizer’s online community about aging fails to impress blogger

If you don’t know about Ronni Bennett’s blog – Time Goes By: what it’s really like to get older – you should.

Core Topics
Health Reform
Aging
Other Topics

It’s one of the most consumer-centered sources of information about aging on the Internet. For the most part, it’s written by people experiencing this stage of life firsthand, not those studying or writing about it from a distance.

Bennett was a longtime journalist before she ran into what she calls “a wall of age discrimination” and ended up forcibly retired. The blog expresses her values: Drop the pretense, tell it like it is, and steer clear of advertising and sales pitches.

Bennett describes the site’s genesis this way:

“It was launched in 2003 after I had spent seven or eight years on a personal research project to find out what it’s like to grow old. There wasn’t much good news. From the popular press to scholarly and medical journals, books, government, advocacy groups and NGOs, one message stood out: aging equals decline, disease and debility. No one had anything good to say about it.

Refusing to believe that my future would be that sad and bleak, and since no one else was was doing it, I decided to write about what it’s really like to get old. I had no illusions then that there would be much audience for such a loser topic but in time, I was happily proved wrong.”

If you spend time on the blog, you’ll find an abundance of riches. In addition to regular posts from Bennett and other contributors, there is a carefully compiled list of blogs by and about elders – a gold mine for reporters. There is Bennett’s touching description of her mom’s final illness and death, a subject that all kinds of writers have been tackling recently in various publications. (More on this later in another blog post)

And there is a weblog, the Elder Storytelling Place, where people can share their day-to-day experiences with humor, tenderness, practicality, or any other approach that seems fitting. I especially like the way Bennett introduces this section:

“Among Carl Jung’s seven tasks of aging is to find meaning in one’s life and one way to help in this task is to pull together, piece by piece, one’s memories – great and small – into a coherent storyline. In doing so, there is a natural shift of our attention inward, says Jung, leading to the removal of regret and to reconciliation. In telling our stories we not only fulfill Jung’s task for ourselves, we pass on the wisdom we have gained to those who listen or read.”

I thought of Time Goes By this week when I encountered the media buzz accompanying a new initiative called “Get Old,” funded by drug giant Pfizer and supported by advocacy organizations such as the National Alliance for Caregiving and Easter Seals.

(See the press release here. For selected media coverage, see the Washington Post‘s write-up and CBS Money Watch’s and USA Today‘s.)

The centerpiece of this project is a new website, www.GetOld.com. In press release speak, the site is touted as a “first-of-its-kind online community” where “people can get and share information, add to the dialogue, and contribute to the growing body of knowledge” about aging.

I imagine Bennett might object to that description. And I’m darned sure she’d object to Pfizer’s sponsorship of this venture as well. (See her recent post, “No Way to Treat a Crabby Elderblogger,” if you have any doubts.)

It’s a savvy move on Pfizer’s part, aligning itself with all those consumer organizations, adopting an attitude of listening to people with an open, curious mindset, positioning itself as a company that helps people live longer and enjoy new experiences. But do not deceive yourself for even an instant: The goal here is to bolster the Pfizer brand and, ultimately, sell more of the drugs that the company links so effectively with longevity and quality of life.

If you have any doubts, see this Pfizer-sponsored video on the company’s “Smart Marketing Page” for the “Get Old” campaign. (I must be getting old: I’ve never encountered a Smart Marketing Page before. I use caps here, as in the press release, to emphatically express the importance of such a page.)

Judith GrahamJudith Graham (@judith_graham), AHCJ’s topic leader on aging, is writing blog posts, editing tip sheets and articles and gathering resources to help our members cover the many issues around our aging society.

If you have questions or suggestions for future resources on the topic, please send them to judith@healthjournalism.org.

Maybe all the participating consumer organizations have received assurances that no cleverly disguised sales pitches will appear on www.GetOld.com and that all information deriving from this project will be unbiased. But, fellow journalists, do you trust that will be the case? And why did so many stories about this initiative ignore that issue and swallow the Gallup & Robinson survey results – the news peg in the press release designed to secure media coverage – hook, line and sinker?

Update:

Bennett sent me some comments about the “Get Old” site after I let her know I was writing this post. I’ve edited them below for length.

“Mostly I object to the website. What a disaster. It violates just about every established guideline for useful, readable, entertaining websites, so much so for elders in both design and content that it’s an insult to us.

As you undoubtedly know, individual elders age at dramatically different rates than people in younger stages of life so that sometimes an 80-year-old’s decline – as in eyesight, for example – can be no more than that of a 50- or 60-year-old. Other times, a 60-year-old can have aged as much as an average 80-something. This also applies to one’s emotional, intellectual and psychic development.

So to section the website by age makes no sense at all, especially when they encourage readers to register their ages so that they can, as the site states, “provide you with stories and information that are relevant and customized for you.” It just doesn’t work that way when talking about elders.

Long before old age, by 40 on average, the majority of us wear reading glasses. But Pfizer has made the text so tiny on their section-front pages, there is no way to know the subject of the item before clicking on it and, even then, the topic is often unclear.

As people age, their eyes have trouble distinguishing between certain colors when they abut one another: red/orange, for example, and blue/green. Yet Pfizer – on that awful “jumble” page of unreadable topics – mixes blue and green boxes that too many elders will blend together.

The site fails aesthetically from page one; there is nothing inviting there, nothing engaging, nothing to pique anyone’s interest. It’s badly conceived and executed.

Barlett & Steele uncover chaos, peril of global drug industry

In Vanity Fair, Donald Barlett and James Steele have devoted more than 6,000 words to chronicling the gaping holes in the global pharmaceutical industry, particularly as pertains to the globalization of clinical trials. Even if you’re familiar with many of the specific incidents covered, their cumulative effect, driven home with forceful and authoritative prose, is brutal. Each paragraph holds another tale of trials gone wrong, children killed and bad results that somehow never came to the attention of American regulators.

globePhoto by amyvdh via Flickr

It used to be that clinical trials were done mostly by academic researchers in universities and teaching hospitals, a system that, however imperfect, generally entailed certain minimum standards. The free market has changed all that. Today it is mainly independent contractors who recruit potential patients both in the U.S. and—increasingly—overseas.

They devise the rules for the clinical trials, conduct the trials themselves, prepare reports on the results, ghostwrite technical articles for medical journals, and create promotional campaigns. The people doing the work on the front lines are not independent scientists. They are wage-earning technicians who are paid to gather a certain number of human beings; sometimes sequester and feed them; administer certain chemical inputs; and collect samples of urine and blood at regular intervals. The work looks like agribusiness, not research.

After neatly setting up each pin with demonstrations of how international the pharmaceutical industry has become, then proceed to knock them all down with examples of industry impunity and FDA weakness.

The F.D.A., the federal agency charged with oversight of the food and drugs that Americans consume, is rife with conflicts of interest. Doctors who insist the drug you take is perfectly safe may be collecting hundreds of thousands of dollars from the company selling the drug. … Quite often, the F.D.A. never bothers to check for interlocking financial interests. In one study, the agency failed to document the financial interests of applicants in 31 percent of applications for new-drug approval. Even when the agency or the company knew of a potential conflict of interest, neither acted to guard against bias in the test results.

Related

WikiLeaks cables: Pfizer used dirty tricks to avoid clinical trial payout in Nigeria

Did PLoS suffer from COI in ghostwriting article?

Remember that examination of Wyeth (now Pfizer)’s ghostwriting practices that ran in PLoS Medicine a few weeks back? Well, Pharmalot’s Ed Silverman reports that things got a fair bit weirder, thanks to an accusation from Wyeth/Pfizer that the article’s author suffered from her own undisclosed conflict of interest. The article mentions author Adriane Fugh-Berman was a paid expert witness in the trial against Wyeth through which the documents were exposed, but never discloses that she’s still engaged as such.

Silverman got in touch with Fugh-Berman, who said she would clarify her status.

Things get a bit muddier when company representatives allege that the journal was intentionally using the article fodder for an anti-Pfizer lawsuit. Silverman does a good job of explaining the whole situation.

Related: Say what? Pfizer calls PLoS out on conflict of interest

Disciplined docs turn up on Pfizer payroll

New Scientist’s Peter Aldhous and Jim Giles created an interesting mash-up of two popular health stories, disciplined caregivers and conflicts of interest, by matching a set of Pfizer disclosures on payments to doctors and researchers in 2009 with discipline records from the FDA and the country’s most populous states. They found 26 matches on the state level and four from the feds, matches which accounted for about one in every 50 Pfizer-paid doctors in the states they’d investigated.

They assembled a number of anecdotes for the story, but the most telling related to a physician who was disciplined for faulty research related to a Pfizer drug, yet still paid by the company to lecture on it.

Other Pfizer experts ran into trouble during their research. Among them is Thomas Gazda of Scottsdale, Arizona, who was paid to lecture about Geodon after being reprimanded by the FDA over irregularities in his conduct of a trial of the same drug’s use in children and adolescents with bipolar disorder – one of whom was given more than the maximum allowable dose for five days. The FDA had earlier told Pfizer to exclude Gazda’s data from the results submitted by Pfizer during its efforts to win approval to use the drug for this purpose.

AHCJ has extensive resources for folks looking to do both sides of the mashup, with tips for investigating conflicts of interest from John Fauber of the Milwaukee Journal Sentinel and recommendations for looking into disciplined caregivers from ProPublica’s Charles Ornstein and Tracy Weber.